Y. Kotliarov, S. Kotliarova, N. Charong, A. Li, J. Walling et al., Correlation Analysis between Single-Nucleotide Polymorphism and Expression Arrays in Gliomas Identifies Potentially Relevant Target Genes, Cancer Research, vol.69, issue.4, pp.1596-603, 2009.
DOI : 10.1158/0008-5472.CAN-08-2496

W. Mueller and A. Von-deimling, Gene Regulation by Methylation, Recent Results Cancer Res, vol.171, pp.217-256, 2009.
DOI : 10.1007/978-3-540-31206-2_13

W. Mueller, C. Nutt, M. Ehrich, M. Riemenschneider, A. Von-deimling et al., Downregulation of RUNX3 and TES by hypermethylation in glioblastoma, Oncogene, vol.32, issue.4, pp.583-93, 2007.
DOI : 10.1038/sj.onc.1209805

T. Kim, S. Zhong, C. Fields, J. Kim, and K. Robertson, Epigenomic Profiling Reveals Novel and Frequent Targets of Aberrant DNA Methylation-Mediated Silencing in Malignant Glioma, Cancer Research, vol.66, issue.15, pp.7490-501, 2006.
DOI : 10.1158/0008-5472.CAN-05-4552

G. Foltz, G. Ryu, J. Yoon, T. Nelson, J. Fahey et al., Genome-Wide Analysis of Epigenetic Silencing Identifies BEX1 and BEX2 as Candidate Tumor Suppressor Genes in Malignant Glioma, Cancer Research, vol.66, issue.13, pp.6665-74, 2006.
DOI : 10.1158/0008-5472.CAN-05-4453

G. Foltz, J. Yoon, H. Lee, T. Ryken, Z. Sibenaller et al., DNA methyltransferase-mediated transcriptional silencing in malignant glioma: a combined whole-genome microarray and promoter array analysis, Oncogene, vol.2, issue.29, 2009.
DOI : 10.1007/s10350-007-0286-6

R. Martinez, F. Setien, C. Voelter, S. Casado, M. Quesada et al., CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme, Carcinogenesis, vol.28, issue.6, 2007.
DOI : 10.1093/carcin/bgm014

R. Martinez and G. Schackert, Epigenetic Aberrations in Malignant Gliomas: An Open Door Leading to Better Understanding and Treatment, Epigenetics, vol.2, issue.3, pp.147-50, 2007.
DOI : 10.4161/epi.2.3.5049

R. Stupp, M. Hegi, W. Mason, M. Van-den-bent, M. Taphoorn et al., Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, The Lancet Oncology, vol.10, issue.5, pp.459-66, 2009.
DOI : 10.1016/S1470-2045(09)70025-7